Correlation of autologous skeletal myoblast survival with changes in left ventricular remodeling in dilated ischemic heart failure
- PMID: 16214511
- DOI: 10.1016/j.jtcvs.2005.02.030
Correlation of autologous skeletal myoblast survival with changes in left ventricular remodeling in dilated ischemic heart failure
Abstract
Objectives: The effect of autologous skeletal myoblast transplantation has not been rigorously studied in the setting of end-stage ischemic heart failure free of concomitant coronary revascularization. The aims of the present study were to determine autologous skeletal myoblast survival and its effects on left ventricular function and remodeling in sheep with dilated ischemic heart failure.
Methods: Ischemic heart failure (left ventricular ejection fraction, 30% +/- 2%; left ventricular end-systolic volume index, 82 +/- 9 mL/m2) was created in sheep (n = 11) with serial left circumflex coronary artery microembolizations. Instruments were inserted for the long-term determination of left ventricular global and regional dimensions, hemodynamics, and pressure-volume analysis after autologous skeletal myoblast transplantation (approximately 3.0 x 10(8) myoblasts; heart failure plus autologous skeletal myoblast group, n = 5) or without (heart failure-control group, n = 6). Measurements were performed in conscious animals.
Results: Autologous skeletal myoblast-derived skeletal muscle was found in all injected animals at 6 weeks. In ischemic heart failure, autologous skeletal myoblast cardiomyoplasty failed to improve systolic (left ventricular ejection fraction, 29% +/- 4%; dP/dT(max), 2863 +/- 152 mm Hg/s; end-systolic elastance, 1.6 +/- 0.22) or diastolic (left ventricular end-diastolic pressure, 21 +/- 2 mm Hg; time constant of relaxation (Tau), 34 +/- 4 ms; dP/dT(min), -1880 +/- 68 mm Hg/s) function. There was, however, attenuation in the left ventricular dilatation after autologous skeletal myoblast transplantation (change in end-systolic volume index, 14% +/- 4% vs 32% +/- 6%; P < .05). The effects of autologous skeletal myoblast-derived skeletal muscle were exclusive to the left ventricular short-axis dimension and dependent on autologous skeletal myoblast survival (R2 = 0.59, P = .006, n = 11).
Conclusions: Autologous skeletal cardiomyoplasty was able to attenuate left ventricular remodeling in sheep with end-stage ischemic heart failure.
Comment in
-
Optimizing cardiac cell therapy: from processing to delivery.J Thorac Cardiovasc Surg. 2005 Oct;130(4):966-8. doi: 10.1016/j.jtcvs.2005.05.047. J Thorac Cardiovasc Surg. 2005. PMID: 16214505 No abstract available.
-
Correlation of autologous skeletal myoblast survival with changes in left ventricular remodeling in dilated ischemic heart failure.J Thorac Cardiovasc Surg. 2006 Jun;131(6):1422. doi: 10.1016/j.jtcvs.2005.11.050. J Thorac Cardiovasc Surg. 2006. PMID: 16733196 No abstract available.
Similar articles
-
Correlation of autologous skeletal myoblast survival with changes in left ventricular remodeling in dilated ischemic heart failure.J Thorac Cardiovasc Surg. 2006 Jun;131(6):1422. doi: 10.1016/j.jtcvs.2005.11.050. J Thorac Cardiovasc Surg. 2006. PMID: 16733196 No abstract available.
-
Autologous skeletal myoblast transplantation improved hemodynamics and left ventricular function in chronic heart failure dogs.J Heart Lung Transplant. 2005 Nov;24(11):1940-9. doi: 10.1016/j.healun.2005.02.024. Epub 2005 Aug 24. J Heart Lung Transplant. 2005. PMID: 16297802
-
Skeletal myoblast sheet transplantation improves the diastolic function of a pressure-overloaded right heart.J Thorac Cardiovasc Surg. 2009 Aug;138(2):460-7. doi: 10.1016/j.jtcvs.2009.02.018. J Thorac Cardiovasc Surg. 2009. PMID: 19619796
-
Skeletal myoblasts as a therapeutic agent.Prog Cardiovasc Dis. 2007 Jul-Aug;50(1):7-17. doi: 10.1016/j.pcad.2007.02.002. Prog Cardiovasc Dis. 2007. PMID: 17631434 Review.
-
Clinical trials in the surgical management of congestive heart failure: surgical ventricular restoration and autologous skeletal myoblast and stem cell cardiomyoplasty.Cardiology. 2004;101(1-3):48-60. doi: 10.1159/000075985. Cardiology. 2004. PMID: 14988626 Review.
Cited by
-
Hyperthermia differently affects connexin43 expression and gap junction permeability in skeletal myoblasts and HeLa cells.Mediators Inflamm. 2014;2014:748290. doi: 10.1155/2014/748290. Epub 2014 Jul 20. Mediators Inflamm. 2014. PMID: 25143668 Free PMC article.
-
Myogenic endothelial cells purified from human skeletal muscle improve cardiac function after transplantation into infarcted myocardium.J Am Coll Cardiol. 2008 Dec 2;52(23):1869-1880. doi: 10.1016/j.jacc.2008.07.064. J Am Coll Cardiol. 2008. PMID: 19038685 Free PMC article.
-
Repairing damaged myocardium: evaluating cells used for cardiac regeneration.Curr Treat Options Cardiovasc Med. 2008 Feb;10(1):59-72. doi: 10.1007/s11936-008-0007-z. Curr Treat Options Cardiovasc Med. 2008. PMID: 18325308
-
Oxygen and oxygenation in stem-cell therapy for myocardial infarction.Life Sci. 2010 Aug 28;87(9-10):269-74. doi: 10.1016/j.lfs.2010.06.013. Epub 2010 Jun 28. Life Sci. 2010. PMID: 20600148 Free PMC article. Review.
-
Tissue-engineered pro-angiogenic fibroblast scaffold improves myocardial perfusion and function and limits ventricular remodeling after infarction.J Thorac Cardiovasc Surg. 2010 Sep;140(3):667-76. doi: 10.1016/j.jtcvs.2009.12.037. Epub 2010 Apr 3. J Thorac Cardiovasc Surg. 2010. PMID: 20363480 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical